Nishitha M M Reddy

基本信息

Career Trajectory

Bio

Following completion of her fellowship at Roswell Park Cancer Institute, she joined the faculty at Vanderbilt-Ingram Cancer Center. Her primary focus is in treating Lymphoid malignancies.

Research Interests

Papers共 189 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Outcomes of Marginal Zone Lymphoma Treated with Ibrutinib in the First-Line Setting in the United States: a Real-World Analysis

Narendranath Epperla,Qiuhong Zhao,Tamara Moyo,Marcus P. Watkins,Montreh Tavakkoli,Celeste Bello,Pallawi Torka,Nishitha Reddy,Colin Thomas,Kaitlin Annunzio,Beth Christian,Stefan K. Barta,Geoffrey Shouse,Adam J. Olszewski,Nancy L. Bartlett

Blood Advancesno. 3 (2023): 549-552

Cited0Views0WOSBibtex

EBV-positive PCNSL in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes Across a Large Multicenter Cohort

Leukemia & lymphoma/Leukemia and lymphoma（2023）

Cited4Views0WOSBibtex

Postibrutinib Relapse Outcomes for Patients with Marginal Zone Lymphoma

Blood Advances（2023）

Cited1Views0WOSBibtex

Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma

BLOOD ADVANCESno. 24 (2023): 7393-7401

Cited6Views0WOSBibtex

Older Patients with Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 U.S. Cancer Centers

American Journal of Hematology（2023）

Cited12Views0WOSBibtex

Zandelisib with Continuous or Intermittent Dosing As Monotherapy or in Combination with Rituximab in Patients with Relapsed or Refractory B-cell Malignancy: a Multicentre, First-in-patient, Dose-Escalation and Dose-Expansion, Phase 1b Trial

John M. Pagel,Jacob Soumerai,Nishitha Reddy,Deepa Jagadeesh,Anastasios Stathis,Adam Asch,Huda Salman,Vaishalee P. Kenkre,Alexia Iasonos,Judith Llorin-Sangalang,Joanne Li,Andrew Zelenetz

LANCET ONCOLOGYno. 8 (2022): 1021-1030

Cited20Views0WOSBibtex

IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): the TIDAL Study

Andrew David Zelenetz,Wojciech Jurczak,Vincent Ribrag,Kim Linton,Graham P. Collins,Javier Lopez-Jimenez,Nishitha Reddy,Andrea Mengarelli,Tycel Jovelle Phillips,Gerardo Musuraca,Oonagh Sheehy,Joanne Li,Weiming Xu,Michel Meyer Azoulay,Richard Ghalie,Pier Luigi Zinzani

Clinical Lymphoma Myeloma & Leukemia（2022）

Cited0Views0WOSBibtex

Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

BLOOD（2022）

Cited0Views0Bibtex

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Jennifer A. Woyach,Ian W. Flinn,Farrukh T. Awan,Herbert Eradat,Danielle Brander,Michael Tees,Sameer A. Parikh,Tycel J. Phillips,Razi Ghori,Nishitha M. Reddy,Mohammed Z. H. Farooqui,John C. Byrd,Deborah M. Stephens

Blood（2022）

Cited22Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Professor

Papers共 189 篇Author StatisticsCo-AuthorSimilar Experts